80(top 5%)
publications
4.0K
citations
28(top 5%)
h-index
1.55(top 10%)
e-Score
759
citing journals
100
times ranked

Publications

80 publications • 4,016 citations • Sorted by year • Download PDF (PDF by citations)
Sort: Year | Citations
#ArticleYearIFCitationsLinks
1Amivantamab Plus Lazertinib in Atypical EGFR-Mutated Advanced Non–Small Cell Lung Cancer: Results From CHRYSALIS-2202623.829Citations (PDF)
2First-Line Aumolertinib (EGFR Tyrosine Kinase Inhibitor) Plus Apatinib (VEGFR Inhibitor) Versus Aumolertinib in EGFR-Mutant Non-Small Cell Lung Cancer Patients: A Randomized, Multicenter, Phase II Trial202669.10Citations (PDF)
3CACA Guidelines for Holistic Integrative Management of Older Adults With Cancer20261.82Citations (PDF)
4Aumolertinib With Carboplatin–Pemetrexed Versus Aumolertinib for Nonsmall Cell Lung Cancer With EGFR and Concomitant Tumor Suppressor Genes (ACROSS2): An Open-Label, Multicenter, Randomized Phase 3 Study2026651.58Citations (PDF)
5Gotistobart or Docetaxel in Metastatic Squamous Non-Small Cell Lung Cancer: Stage 1 of the Randomized Phase 3 PRESERVE-003 Trial
Nature Medicine, 32, 2245-2253
202651.22Citations (PDF)
6Real-World Serplulimab Plus Chemotherapy for Extensive-Stage Small Cell Lung Cancer in China: An External Validation of ASTRUM-005 Trial20269.11Citations (PDF)
7Oral KRAS G12D Inhibitor GFH375 for Previously Treated Advanced Solid Tumors With KRASG12D Mutations: A Phase 1 Trial.
Nature Medicine, 32, 3302-3312
202651.21Citations (PDF)
8A Plain Language Summary of Results From the CHOICE-01 Trial of Toripalimab Plus Chemotherapy for Advanced Non-Small Cell Lung Cancer (NSCLC)
Future Oncology, 21, 515-522
20253.10Citations (PDF)
9Glecirasib in KRASG12C-Mutated Nonsmall-Cell Lung Cancer: A Phase 2b Trial202551.244Citations (PDF)
10A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Socazolimab or Placebo Combined With Carboplatin and Etoposide in the First-Line Treatment of Extensive-Stage Small Cell Lung Cancer202569.117Citations (PDF)
11A B7H3-Targeting Antibody–Drug Conjugate in Advanced Solid Tumors: A Phase 1/1b Trial
Nature Medicine, 31, 1949-1957
202551.2124Citations (PDF)
12Efficacy and Safety of Dacomitinib in Treatment-Naïve Patients With Advanced NSCLC and Brain Metastasis: A Multicenter Cohort Study20255.02Citations (PDF)
13Potential Biomarkers of Primary Resistance to First- and Second-Generation EGFR-TKIs in Non-Small-Cell Lung Cancer: A Real-World Study20254.22Citations (PDF)
14Harnessing Local and System Immune Profiling Delineating Differential Responders to First-Line Sintilimab (Anti-PD-1 Antibody) Combined With Chemotherapy in Extensive-Stage Small Cell Lung Cancer: An Exploratory Biomarker Analysis of a Phase II Study202569.110Citations (PDF)
15First-Line Serplulimab Plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer: Updated Results and Biomarker Analysis From the ASTRUM-005 Randomized Clinical Trial
Cancer Communications, 45, 990-1009
202516.726Citations (PDF)
16Immune Checkpoint Inhibitor-Based Therapy as the First-Line Treatment for Advanced Non-Small Cell Lung Cancer: Efficacy, Challenges, and Future Perspectives
Thoracic Cancer, 16, e70113
20252.99Citations (PDF)
17Expert Consensus on the Diagnosis and Treatment of Malignant Mesothelioma of the Tunica Vaginalis Testis
iMetaMed, 1, e70003
20250.03Citations (PDF)
18First-Line Sacituzumab Tirumotecan With Tagitanlimab in Advanced Non-Small-Cell Lung Cancer: A Phase 2 Trial202551.225Citations (PDF)
19Efficacy and Safety of Glecirasib in Solid Tumors With KRAS G12C Mutation: A Pooled Analysis of Two Phase I/II Trials
Cancer Communications, 45, 1500-1512
202516.716Citations (PDF)
20PACIFIC-5: A Phase III Clinical Trial of Consolidation Durvalumab in Patients With Unresectable Stage III NSCLC and No Progression After Concurrent or Sequential Chemoradiotherapy202544.418Citations (PDF)
21A Phase Ib/II Study of Cadonilimab (PD-1/CTLA-4 Bispecific Antibody) Plus Anlotinib as First-Line Treatment in Patients With Advanced Non-Small Cell Lung Cancer20248.146Citations (PDF)
22Camrelizumab Combined With Apatinib and Nanoparticle Albumin-Bound Paclitaxel in Lung Adenocarcinoma (CAPAP-Lung): A Single-Arm Phase II Study
EClinicalMedicine, 67, 102403
202413.510Citations (PDF)
23Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor–Mutated Metastatic Non–Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Final Results of CheckMate 722202423.8175Citations (PDF)
24Long-Term Survival of a Patient With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer (NSCLC) and Untreated Multiple Brain Metastases Treated With Zorifertinib: A Case Report
Thoracic Cancer, 15, 1325-1329
20242.91Citations (PDF)
25Vebreltinib for Advanced Non–Small Cell Lung Cancer Harboring c-Met Exon 14 Skipping Mutation: A Multicenter, Single-Arm, Phase II KUNPENG Study202423.848Citations (PDF)
26Sintilimab in Combination With Stereotactic Body Radiotherapy and Granulocyte-Macrophage Colony-Stimulating Factor in Metastatic Non-Small Cell Lung Cancer: The Multicenter SWORD Phase 2 Trial202418.125Citations (PDF)
27Phase Ib/II Study on the Safety, Tolerability, and Preliminary Efficacy of Pegylated Irinotecan (JK1201I) as Second-Line Monotherapy for Patients With Small-Cell Lung Cancer
Cancer Medicine, 13, e70059
20243.82Citations (PDF)
28Efficacy in Patients With EGFR-Positive Non-Small-Cell Lung Cancer Treated With Dacomitinib Who Had Skin Adverse Events: Post Hoc Analyses From ARCHER 1050
Future Oncology, 20, 2971-2982
20243.15Citations (PDF)
29Toripalimab Plus Chemotherapy for First Line Treatment of Advanced Non-Small Cell Lung Cancer (CHOICE-01): Final OS and Biomarker Exploration of a Randomized, Double-Blind, Phase 3 Trial202469.135Citations (PDF)
30Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non–Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01)202323.8183Citations (PDF)
31Rh-Endostatin Plus Camrelizumab and Chemotherapy in First-Line Treatment of Advanced Non-Small Cell Lung Cancer: A Multicenter Retrospective Study
Cancer Medicine, 12, 7724-7733
20233.818Citations (PDF)
32Intracranial Activity of Selpercatinib in Chinese Patients With Advanced RET Fusion–Positive Non–Small-Cell Lung Cancer in the Phase II LIBRETTO-321 Trial20233.811Citations (PDF)
33First-Line Immunotherapy for Advanced Non-Small Cell Lung Cancer: Current Progress and Future Prospects20236.312Citations (PDF)
34A Novel Third-Generation EGFR Tyrosine Kinase Inhibitor Abivertinib for EGFR T790M-Mutant Non–Small Cell Lung Cancer: A Multicenter Phase I/II Study20229.521Citations (PDF)
35Comprehensive Characterization of the Genomic Landscape in Chinese Pulmonary Neuroendocrine Tumors Reveals Prognostic and Therapeutic Markers (CSWOG-1901)
Oncologist, 27, e116-e125
20225.013Citations (PDF)
36Three-Year Follow-Up and Patient-Reported Outcomes From CheckMate 078: Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced Non-Small Cell Lung Cancer
Lung Cancer, 165, 71-81
20224.922Citations (PDF)
37Genomic Correlates of Programmed Cell Death Ligand 1 (PD-L1) Expression in Chinese Lung Adenocarcinoma Patients20227.213Citations (PDF)
38An Evaluation of Aumolertinib for the Treatment of EGFR T790M Mutation-Positive Non-Small Cell Lung Cancer20223.522Citations (PDF)
39Clinical and Genomic Features of Chinese Lung Cancer Patients With Germline Mutations202218.136Citations (PDF)
40Anlotinib for Patients With Small Cell Lung Cancer and Baseline Liver Metastases: A Post Hoc Analysis of the ALTER 1202 Trial
Cancer Medicine, 11, 1081-1087
20223.822Citations (PDF)
41The Efficacy and Safety of Immune Checkpoint Inhibitors Combined With Chemotherapy or Anti-Angiogenic Therapy as a Second-Line or Later Treatment Option for Advanced Non-Small Cell Lung Cancer: A Retrospective Comparative Cohort Study20222.814Citations (PDF)
42Sintilimab Versus Docetaxel as Second-Line Treatment in Advanced or Metastatic Squamous Non-Small-Cell Lung Cancer: An Open-Label, Randomized Controlled Phase 3 Trial (ORIENT-3)
Cancer Communications, 42, 1314-1330
202216.759Citations (PDF)
43Dacomitinib Induces Objective Responses in Metastatic Brain Lesions of Patients With EGFR-Mutant Non-Small-Cell Lung Cancer: A Brief Report
Lung Cancer, 152, 66-70
20214.931Citations (PDF)
44Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial.202123.8258Citations (PDF)
45Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced Non-Small Cell Lung Cancer: 2-Year Follow-Up From a Randomized, Open-Label, Phase 3 Study (CheckMate 078)
Lung Cancer, 152, 7-14
20214.957Citations (PDF)
46Case Report: Therapeutic Response to Chemo-Immunotherapy in an Advanced Large Cell Lung Carcinoma Patient With Low Values of Multiple Predictive Biomarkers20216.93Citations (PDF)
47Prediction of Egfr Mutation Status in Lung Adenocarcinoma Using Multi-Source Feature Representations20217Citations (PDF)
48Efficacy, Safety, and Genetic Analysis of Furmonertinib (AST2818) in Patients With EGFR T790M Mutated Non-Small-Cell Lung Cancer: A Phase 2b, Multicentre, Single-Arm, Open-Label Study202128.0107Citations (PDF)
49Icotinib Versus Chemotherapy as Adjuvant Treatment for Stage II–IIIA EGFR-Mutant Non-Small-Cell Lung Cancer (EVIDENCE): A Randomised, Open-Label, Phase 3 Trial202128.0173Citations (PDF)
50Sintilimab, Stereotactic Body Radiotherapy and Granulocyte–Macrophage Colony Stimulating Factor as Second-Line Therapy for Advanced Non-Small Cell Lung Cancer: Safety Run-In Results of a Multicenter, Single-Arm, Phase II Trial20213.923Citations (PDF)
51Next-Generation Sequencing Assisted Diagnosis of Cervical Metastasis in EGFR-Mutated Lung Adenocarcinoma: A Case Report
Thoracic Cancer, 12, 2622-2627
20212.94Citations (PDF)
52Effectiveness of Anlotinib in Patients With Small-Cell Lung Cancer and Pleural Effusion: Subgroup Analysis From a Randomized, Multicenter, Phase II Study
Thoracic Cancer, 12, 3039-3045
20212.99Citations (PDF)
53Genomic Signatures Define Three Subtypes of EGFR-Mutant Stage II–III Non-Small-Cell Lung Cancer With Distinct Adjuvant Therapy Outcomes202118.174Citations (PDF)
54Case Report: Tissue Origin Identification for Cancer of Unknown Primary: Gene Expression Profiling Approach20213.54Citations (PDF)
55Disparity in Clinical Outcomes Between Pure and Combined Pulmonary Large-Cell Neuroendocrine Carcinoma: A Multi-Center Retrospective Study
Lung Cancer, 139, 118-123
20204.944Citations (PDF)
56Quality of Life With Adjuvant Gefitinib Versus Vinorelbine Plus Cisplatin in Patients With Completely Resected Stage II–IIIA (N1–N2) EGFR-Mutant Non-Small-Cell Lung Cancer: Results From the ADJUVANT (CTONG1104) Study
Lung Cancer, 150, 164-171
20204.910Citations (PDF)
57Silencing of Long Non-Coding RNA SOX21-AS1 Inhibits Lung Adenocarcinoma Invasion and Migration by Impairing TSPAN8 via Transcription Factor GATA620208.418Citations (PDF)
58Real-World Scenario of Patients With Lung Cancer Amid the Coronavirus Disease 2019 Pandemic in the People’s Republic of China20203.016Citations (PDF)
59Safety and Efficacy of Aprepitant as Mono and Combination Therapy for the Prevention of Emetogenic Chemotherapy-Induced Nausea and Vomiting: Post-Marketing Surveillance in China20201.37Citations (PDF)
60Circulating Tumor DNA Clearance Predicts Prognosis Across Treatment Regimen in a Large Real-World Longitudinally Monitored Advanced Non-Small Cell Lung Cancer Cohort20202.893Citations (PDF)
61Safety, Clinical Activity, and Pharmacokinetics of Alflutinib (AST2818) in Patients With Advanced NSCLC With EGFR T790M Mutation202015.0100Citations (PDF)
62Peripheral Blood Biomarkers Associated With Outcome in Non-Small Cell Lung Cancer Patients Treated With Nivolumab and Durvalumab Monotherapy20203.542Citations (PDF)
63Abstract CT127: A Phase I Study of cMET Inhibitor Bozitinib in Patients With Advanced NSCLC Harboring cMET Alterations
Cancer Research, 80, CT127-CT127
202011.820Citations (PDF)
64The Unique Spatial-Temporal Treatment Failure Patterns of Adjuvant Gefitinib Therapy: A Post Hoc Analysis of the ADJUVANT Trial (CTONG 1104)201915.064Citations (PDF)
65Irinotecan Plus S-1 Versus S-1 in Patients With Previously Treated Recurrent or Metastatic Esophageal Cancer (ESWN 01): A Prospective Randomized, Multicenter, Open-Labeled Phase 3 Trial201916.725Citations (PDF)
66Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial.201915.0337Citations (PDF)
67The Impact of Previous Therapy Strategy on the Efficiency of Anlotinib Hydrochloride as a Third-Line Treatment on Patients With Advanced Non-Small Cell Lung Cancer (NSCLC): A Subgroup Analysis of ALTER0303 Trial20192.832Citations (PDF)
68Population Pharmacokinetics and Individualized Lobaplatin Regimen for the Treatment of Chinese Small Cell Lung Cancer in the Elderly20192.20Citations (PDF)
69Association of microRNA-423 rs6505162 C>A Polymorphism With Susceptibility and Metastasis of Colorectal Carcinoma20182.217Citations (PDF)
70Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II–IIIA (N1–N2) EGFR-Mutant NSCLC (Adjuvant/CTONG1104): A Randomised, Open-Label, Phase 3 Study201828.5503Citations (PDF)
71Immunotherapy for Non-Small Cell Lung Cancers: Biomarkers for Predicting Responses and Strategies to Overcome Resistance
BMC Cancer, 18, 1-10
20184.349Citations (PDF)
72Clinical Characterization of ERBB2 Exon 20 Insertions and Heterogeneity of Outcomes Responding to Afatinib in Chinese Lung Cancer Patients20182.633Citations (PDF)
73Patient-Derived Tumor Immune Microenvironments in Patient-Derived Xenografts of Lung Cancer20189.414Citations (PDF)
74Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non–Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial
JAMA Oncology, 4, 1569-1575
201819.8583Citations (PDF)
75A Consensus on Immunotherapy From the 2017 Chinese Lung Cancer Summit Expert Panel20182.89Citations (PDF)
76Adenocarcinoma of the Lung With EGFR Gene Mutation and Subsequent Resistance Mechanisms Exploration: Case Report20172.61Citations (PDF)
77miR‑96 Induces Cisplatin Chemoresistance in Non‑Small Cell Lung Cancer Cells by Downregulating SAMD9
Oncology Letters, 11, 945-952
20162.461Citations (PDF)
78Effect of Transporter and DNA Repair Gene Polymorphisms to Lung Cancer Chemotherapy Toxicity
Tumor Biology, 37, 2275-2284
20163.418Citations (PDF)
79Mefunidone Attenuates Tubulointerstitial Fibrosis in a Rat Model of Unilateral Ureteral Obstruction
PLoS ONE, 10, e0129283
20153.228Citations (PDF)
80Fluorofenidone Offers Improved Renoprotection at Early Interventions During the Course of Diabetic Nephropathy in Db/Db Mice via Multiple Pathways
PLoS ONE, 9, e111242
20143.210Citations (PDF)